First Light Asset Management LLC Buys 1,485,664 Shares of TriSalus Life Sciences, Inc. $TLSI

First Light Asset Management LLC boosted its stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) by 29.3% during the second quarter, HoldingsChannel reports. The firm owned 6,552,491 shares of the company’s stock after buying an additional 1,485,664 shares during the period. TriSalus Life Sciences comprises about 1.8% of First Light Asset Management LLC’s portfolio, making the stock its 20th biggest holding. First Light Asset Management LLC owned 0.11% of TriSalus Life Sciences worth $29,814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of TLSI. BlackRock Inc. purchased a new position in TriSalus Life Sciences in the 2nd quarter worth approximately $12,099,000. Perkins Capital Management Inc. bought a new position in shares of TriSalus Life Sciences in the 1st quarter worth $920,000. Nantahala Capital Management LLC bought a new position in shares of TriSalus Life Sciences in the 2nd quarter worth $4,550,000. Wasatch Advisors LP purchased a new stake in shares of TriSalus Life Sciences during the 1st quarter valued at $5,752,000. Finally, Empire Financial Management Company LLC raised its position in shares of TriSalus Life Sciences by 316.9% during the 1st quarter. Empire Financial Management Company LLC now owns 300,275 shares of the company’s stock valued at $1,201,000 after buying an additional 228,248 shares in the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on TLSI. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Lake Street Capital dropped their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, HC Wainwright began coverage on TriSalus Life Sciences in a research report on Wednesday. They set a “buy” rating and a $11.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.67.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $4.76 on Thursday. TriSalus Life Sciences, Inc. has a 52-week low of $2.20 and a 52-week high of $7.95. The stock has a market capitalization of $293.12 million, a price-to-earnings ratio of -3.66 and a beta of 0.44. The company has a fifty day moving average of $4.75 and a 200-day moving average of $4.33. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $11.41 million during the quarter, compared to the consensus estimate of $10.27 million.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.